Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon.
10.3857/roj.2014.32.3.187
- Author:
Hyunjung KIM
1
;
Jun Won KIM
;
Sung Joon HONG
;
Koon Ho RHA
;
Chang Geol LEE
;
Seung Choul YANG
;
Young Deuk CHOI
;
Chang Ok SUH
;
Jaeho CHO
Author Information
1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. jjhmd@yuhs.ac
- Publication Type:Original Article
- Keywords:
Prostatic neoplasm;
Hypofractionation;
Rectal Balloon;
Radiotherapy;
Intensity modulation
- MeSH:
Follow-Up Studies;
Humans;
Medical Records;
Prostatic Neoplasms*;
Radiotherapy;
Radiotherapy, Conformal;
Radiotherapy, Intensity-Modulated*;
Survival Rate;
Treatment Outcome*
- From:Radiation Oncology Journal
2014;32(3):187-197
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We aimed to analyze the treatment outcome and long-term toxicity of 70 Gy hypofractionated intensity-modulated radiotherapy (IMRT) for localized prostate cancer using a customized rectal balloon. MATERIALS AND METHODS: We reviewed medical records of 86 prostate cancer patients who received curative radiotherapy between January 2004 and December 2011 at our institution. Patients were designated as low (12.8%), intermediate (20.9%), or high risk (66.3%). Thirty patients received a total dose of 70 Gy in 28 fractions over 5 weeks via IMRT (the Hypo-IMRT group); 56 received 70.2 Gy in 39 fractions over 7 weeks via 3-dimensional conformal radiotherapy (the CF-3DRT group, which served as a reference for comparison). A customized rectal balloon was placed in Hypo-IMRT group throughout the entire radiotherapy course. Androgen deprivation therapy was administered to 47 patients (Hypo-IMRT group, 17; CF-3DRT group, 30). Late genitourinary (GU) and gastrointestinal (GI) toxicity were evaluated according to the Radiation Therapy Oncology Group criteria. RESULTS: The median follow-up period was 74.4 months (range, 18.8 to 125.9 months). The 5-year actuarial biochemical relapse-free survival rates for low-, intermediate-, and high-risk patients were 100%, 100%, and 88.5%, respectively, for the Hypo-IMRT group and 80%, 77.8%, and 63.6%, respectively, for the CF-3DRT group (p < 0.046). No patient presented with acute or late GU toxicity > or =grade 3. Late grade 3 GI toxicity occurred in 2 patients (3.6%) in the CF-3DRT group and 1 patient (3.3%) in the Hypo-IMRT group. CONCLUSION: Hypo-IMRT with a customized rectal balloon resulted in excellent biochemical control rates with minimal toxicity in localized prostate cancer patients.
